BURLINGTON, Mass., Sept. 30, 2015 /PRNewswire/ -- Decision Resources Group finds that a majority of surveyed U.S. gastroenterologists are highly familiar with Entyvio, with 62% reporting they have prescribed Entyvio to at least one of their UC or CD patients. Many surveyed and interviewed physicians cite Entyvio's new mechanism of action and its efficacy as a perceived advantage as lack or loss of response in patients using anti-TNF agents is a substantial concern. Although clinical data suggest weaker efficacy in CD than UC, and that the theoretical risk of PML is still a concern for many surveyed physicians, a majority of gastroenterologists indicate a high level of willingness to prescribe Entyvio for both UC and CD. 

Other key findings from the LaunchTrends report entitled "Entyvio Wave 3 (US)":

  • The perception that the benefits of Entyvio outweigh the risks in both UC and CD increased among surveyed gastroenterologists in each successive Wave.
  • The most commonly reported disadvantage of Entyvio in Wave 3 was cost/formulary access, nearly double from what was reported in Wave 2.
  • Primary and secondary failure are the most common reasons for discontinuation of Entyvio for UC and CD; however, cumbersome MCO restrictions were also cited as a reason more often than other biologics.
  • Entyvio is being used primarily after failure with other biologics (e.g., Remicade, Humira) and/or for patients who are corticosteroid dependent; however, an increase in biologic-naive treated patients was observed in Wave 3 compared with Waves 1 and 2.  

Comments from Decision Resources Group Analyst (Michael Darcy):

  • "As familiarity with Entyvio has increased, we observed an associated shift towards a positive perception of the drug's efficacy and safety profile. Overall satisfaction with Entyvio was quite high, including its use in CD, despite the weaker clinical data from pivotal trials compared with UC."
  • "We expect Entyvio to remain a second or third-line biologic for the foreseeable future for both UC and CD, with some use as a first-line biologic. Takeda has suggested they are developing an SC formulation as well as plans to perform comparator trials in the future; positive outcomes from these efforts would provide broader incentives for physicians to use Entyvio earlier in the treatment algorithm."

For more information on purchasing this report, please email questions@teamDRG.com.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 14 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.

Media contact:
SHIFT Communications
Theresa Masnik
617.779.1871
dresourcesgroup@shiftcomm.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Increasingly Favorable Eylea Performance Perceptions, Especially Among Retinal Specialists, Strengthens Second-Line Position Behind Avastin in the Wet AMD Market

View Now